Lyell Immunopharma Announces 1-for-20 Reverse Stock Split Effective May 30, 2025
Lyell Immunopharma Inc. announced a reverse stock split at a ratio of 1-for-20, effective May 30, 2025. This move will consolidate every 20 shares of the company's common stock into one share, without altering the par value per share. The company's stock will trade on a split-adjusted basis on the Nasdaq Global Select Market starting June 2, 2025, under the new CUSIP number 55083R203. Following the split, the number of outstanding shares will reduce from approximately 296 million to around 14.8 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-129448), on May 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。